|
" Merkel cell carcinoma: long-term follow-up of a single institution series and clinical outcomes by immunological status "
Dasanu, Constantin A; Del Rosario, Michael; Codreanu, Ion; Lu, Yani; Farrell, Stephanie; Hyams, David M; Plaxe, Steven C
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
924532
|
| Doc. No
|
:
|
LA7697x76f
|
| Language of Document
|
:
|
English
|
| Main Entry
|
:
|
Dasanu, Constantin A; Del Rosario, Michael; Codreanu, Ion; Lu, Yani; Farrell, Stephanie; Hyams, David M; Plaxe, Steven C
|
| Title & Author
|
:
|
Merkel cell carcinoma: long-term follow-up of a single institution series and clinical outcomes by immunological status [Article]\ Dasanu, Constantin A; Del Rosario, Michael; Codreanu, Ion; Lu, Yani; Farrell, Stephanie; Hyams, David M; Plaxe, Steven C
|
| Title of Periodical
|
:
|
Dermatology Online Journal
|
| Volume/ Issue Number
|
:
|
25/2
|
| Date
|
:
|
2019
|
| Abstract
|
:
|
Merkel cell carcinoma (MCC) usually arises in sun-exposed areas of older patients and might be more aggressive in the immunocompromised. We performed a retrospective chart review of 40 consecutive MCC patients treated at our institution between the years 2006-2017. Clinical and epidemiologic data were utilized and therapy and survival were analyzed. Compared to Surveillance, Epidemiology, and End Results (SEER) data, our population was entirely Caucasian (100% versus 95%; P=0.11) and male predominant (75% versus 63%; P=0.11). The median age was 76. The patients more often had Tumor-Node-Metastasis (TNM) stage I disease (50% versus 39%; P=0.00003) and a primary tumor size<2cm (57.5% versus 34%; P<0.01). They received more frequently lymph node dissection (70% versus 63%, P=0.002) compared with the SEER findings. We identified a subset of immunocompromised patients (n=10) who presented with more stage III disease (40% versus 33%; P=0.021). Time to death averaged 290.1 days in this subset versus 618.2 days (P<0.001) in immunocompetent patients and their likelihood of death was 5 times higher. As clinical outcomes in MCC patients vary by immunological status, a multidisciplinary tumor-board approach may better optimize individual patient management.
|
| |